SIGNAL
PROXY INTELLIGENCE
New York, NY – 2026-08-05 · Ticker: NASDAQ:CVKD
Signal Proxy Intelligence Recommends Full Support for All Five Items at CADRENAL THERAPEUTICS, INC. Annual Meeting
Independent research firm publishes item-by-item recommendations on all five ballot measures within 43 hours of the company’s proxy filing. (Within SPI’s standing 48-hour / T+2 commitment.)
NEW YORK, NY — Signal Proxy Intelligence, the independent proxy research division of Signal Law Group, today published its recommendations for the Sept. 24, 2026 annual meeting of CADRENAL THERAPEUTICS, INC. (NASDAQ:CVKD). SPI issued a recommendation on each of the five items on the ballot, published 43 hours after the company’s definitive proxy statement was accepted on EDGAR.
Reviewing the ballot from the perspective of the common shareholder and using publicly available information only, SPI assigned the meeting a concern band of Routine. The firm recommends FOR on the advisory vote on executive compensation, citing that as of the Record Date, 264,587 shares remained available for future issuance under the 2022 Plan.
On the election of directors, SPI recommends FOR the director nominees as presented on the ballot.
“This ballot presented no divergences from the board’s recommendations. Each item was assessed under our published framework, and the full rationale for every recommendation is documented in the report.”
— Hayden Smith, Head of Proxy Research
SPI will publish a separate post-meeting divergence report comparing its recommendations to those of the incumbent proxy advisors after the meeting results are available.
The complete item-by-item analysis, including the rationale for each recommendation, is available at https://www.signallawgroup.com/proxies/cadrenal-therapeutics-inc-2026-09-24/.
Ballot Summary: Recommendation by Item
| Item | Title | SPI Recommendation |
|---|---|---|
| 1 | Election of the Class I director named in the accompanying proxy statement to our Board of Directors, to serve a three-year term expiring at the 2029 Annual Meeting of Stockholders and until such director’s successor is duly elected and qualified | FOR |
| 2 | To ratify the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending on December 31, 2026. | FOR |
| 3 | To approve an amendment to the Company’s 2022 Successor Equity Incentive Plan, as amended (the “2022 Plan”), in substantially the form attached to the accompanying proxy statement as Annex A, to increase the number of shares of the Company’s Common Stock that will be available for awards under the 2022 Plan by 323,542 shares to 1,000,000 shares (the “Plan Amendment Proposal”). | FOR |
| 4 | To approve, pursuant to Nasdaq Rule 5635(d), the issuance of up to 960,000 shares of the Company’s Common Stock upon the exercise of Series C-1 warrants, which warrants were issued in connection with a private placement offering that closed on July 1, 2026 (the “Warrant Exercise Proposal”). | FOR |
| 5 | To approve an adjournment of the 2026 Annual Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Plan Amendment Proposal and/or the Warrant Exercise Proposal. | FOR |
About Signal Proxy Intelligence
SPI is the independent proxy research division of Signal Law Group, an independent research and investigations firm. SPI publishes FOR / AGAINST / WITHHOLD recommendations on every item of every covered proxy ballot within 48 hours of filing, analyzing each measure from the perspective of the common shareholder using publicly available information. SPI accepts no revenue from the companies it covers. Every SPI recommendation is timestamped at publication, fingerprinted, and reconciled against the company’s reported vote.
Media contact
Rochelle Welner
contact@signallawgroup.com
# # #
SPI is an operating company of Signal Law Group, an independent research and investigations firm. SPI is not a law firm, does not provide legal advice, and is not an investment adviser. The recommendations and analysis in this release are independent research provided for informational purposes only. They do not constitute voting advice, investment advice, a recommendation to buy or sell securities, or a solicitation of any kind. Recipients should conduct their own independent analysis and consult their own advisors before making any voting or investment decision. SPI accepts no revenue from the companies it covers.
